Evidence map›Paper›PMID 30416963›Full record

ArticleBiochimie open2018

Vanadate inhibits transcription of the rat insulin receptor gene via a proximal sequence of the 5'flanking region.

Sylvie Bortoli, Martine Collinet, Bernard Desbuquois

Open access · hybridAbstract read
In one paragraph

Article in Biochimie open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. The rs1634330 Polymorphisms in theInternational journal of endocrinology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sylvie BortoliINSERM UMR 1124, UFR des Sciences Fondamentales et Biomédicales, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Martine CollinetINSERM UMR 1124, UFR des Sciences Fondamentales et Biomédicales, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Bernard DesbuquoisINSERM U1016, Institut Cochin, CNRS UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Délégation Paris 5 · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vanadate, a protein tyrosine phosphatase inhibitor which elicits insulin-like effects, has previously been shown to inhibit expression of the insulin receptor gene at the transcriptional level in rat hepatoma cells. In an attempt to identify the DNA sequence and transcription factors potentially involved in this effect, a fragment of the proximal 5'flanking region of the IR gene (-1143/-252 upstream the ATG codon) has been cloned and functionally characterized. RNase protection allowed the identification of several transcription start sites in the conserved region of the gene, among which two major sites at -455 and -396. Upon fusion to the luciferase gene and transient transfection into hepatoma cells, the -1143/-252 fragment showed promoter activity. This was unaffected by deletion of the -1143/-761 sequence, but markedly decreased (90%) by additional deletion of the -760/-465 sequence. Treatment of hepatoma cells with vanadate led to a dose-dependent decrease in promoter activity of the 1143/-252, -760/-252 and -464/-252 constructs (change relative to untreated cells, 40, 55 and 23% at 125 μM, and 70, 85 and 62% at 250 μM, respectively). These data suggest that although the entire DNA sequence upstream the transcription start sites is probably involved in vanadate-induced inhibition, the short sequence downstream of position -464 and is sufficient for inhibition. Potential targets of vanadate are the transcription factors FoxO1 and HMGA1, two downstream targets of the insulin signaling pathway which have been shown to mediate the inhibitory effect of insulin on IR gene expression.

Indexed as

C/EBPβ, C/CAAT/enhancer binding protein βFoxO1, Forkhead box protein O1Gene transcriptionHepatoma cellsHMGA1, high mobility group A1 proteinHNF4, hepatocyte nuclear factor 4IGFBP-1, insulin-like growth factor binding protein 1Insulin receptorIR, insulin receptorLiverPEPCK, phosphoenolpyruvate carboxykinasePI3K, phosphatidyl inositol 3-kinaseRatSINE, short interspersed nuclear elementSp1, specificity protein 1STZ, streptozotocinTCF7L2, T-cell specific transcription factor 7-like 2Vanadate

Identifiers

PMID30416963
PMCPMC6205930
OpenAlexW2896920433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.